MTOR directly inhibits cancer immunity by promoting tumor expression of programmed death-ligand 1 (PD-L1) and thus creates a tumor microenvironment resistant to immune attack.34,35 Therefore, we investigated whether MET could suppress liver cancer immunogenicity through the MTOR signaling pathway. The gene discussed is CD274; the disease is cancer.